Pyxis Oncology (PYXS)
Pyxis Oncology on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.3M
Short interest
settlement 2026-10-15
3.5
Days to cover
-0.6 days vs prior
74.1%
Short share of volume
2026-11-02
31
Fails to deliver
settlement 2026-09-30
Tue 10 Nov
Next earnings
estimated date
price not stated in the filing
Insider flow, 90 days
1 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in PYXS is 4,345,953 shares, down 332,569 shares over the last month. Over the last 48 readings it ranged from 1,733,403 shares (31 December 2025) to 7,424,946 shares (15 January 2025). At the reported average volume of 1.3M shares a day that is 3.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/pyxs" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 4,345,953 | -11.1% | 1,253,809 | 3.47 |
| 2026-09-30 | 4,886,652 | +4.5% | 1,207,832 | 4.05 |
| 2026-09-15 | 4,678,522 | +17.9% | 1,282,071 | 3.65 |
| 2026-08-31 | 3,968,105 | -10.3% | 569,963 | 6.96 |
| 2026-08-14 | 4,425,542 | +6.1% | 2,219,479 | 1.99 |
| 2026-07-31 | 4,172,154 | +28.2% | 996,532 | 4.19 |
| 2026-07-15 | 3,253,653 | +42.1% | 1,045,845 | 3.11 |
| 2026-06-30 | 2,289,798 | +13.6% | 1,838,587 | 1.25 |
| 2026-06-15 | 2,015,710 | +15.7% | 415,478 | 4.85 |
| 2026-05-29 | 1,741,743 | -3.8% | 607,711 | 2.87 |
| 2026-05-15 | 1,809,793 | -8.9% | 855,956 | 2.11 |
| 2026-04-30 | 1,986,201 | -12.5% | 360,768 | 5.51 |
| 2026-04-15 | 2,269,065 | -14.7% | 402,636 | 5.64 |
| 2026-03-31 | 2,660,931 | +6.8% | 360,879 | 7.37 |
| 2026-03-13 | 2,490,249 | -1.4% | 323,380 | 7.70 |
| 2026-02-27 | 2,525,155 | +3.4% | 256,287 | 9.85 |
| 2026-02-13 | 2,442,905 | +2.4% | 645,837 | 3.78 |
| 2026-01-30 | 2,386,094 | +3.4% | 605,707 | 3.94 |
| 2026-01-15 | 2,307,831 | +33.1% | 1,930,381 | 1.20 |
| 2025-12-31 | 1,733,403 | -10.3% | 2,886,868 | 1.00 |
| 2025-12-15 | 1,933,041 | -57.3% | 645,262 | 3.00 |
| 2025-11-28 | 4,523,744 | -0.4% | 590,643 | 7.66 |
| 2025-11-14 | 4,541,093 | +4.1% | 947,872 | 4.79 |
| 2025-10-31 | 4,361,521 | +2.6% | 559,670 | 7.79 |
| 2025-10-15 | 4,250,799 | +2.9% | 1,088,009 | 3.91 |
| 2025-09-30 | 4,131,340 | -5.2% | 686,661 | 6.02 |
| 2025-09-15 | 4,359,697 | +0.6% | 1,049,002 | 4.16 |
| 2025-08-29 | 4,334,176 | -13.9% | 570,251 | 7.60 |
| 2025-08-15 | 5,032,348 | +7.2% | 333,358 | 15.10 |
| 2025-07-31 | 4,695,721 | -1.8% | 394,766 | 11.89 |
| 2025-07-15 | 4,781,095 | -5.6% | 440,117 | 10.86 |
| 2025-06-30 | 5,064,919 | -18.1% | 1,005,370 | 5.04 |
| 2025-06-13 | 6,180,200 | -4.5% | 454,082 | 13.61 |
| 2025-05-30 | 6,472,521 | -8.2% | 348,509 | 18.57 |
| 2025-05-15 | 7,048,248 | -2.6% | 521,288 | 13.52 |
| 2025-04-30 | 7,233,818 | +1.4% | 584,341 | 12.38 |
| 2025-04-15 | 7,131,225 | -2.8% | 465,528 | 15.32 |
| 2025-03-31 | 7,336,969 | +6.0% | 478,094 | 15.35 |
| 2025-03-14 | 6,924,016 | -1.2% | 485,113 | 14.27 |
| 2025-02-28 | 7,008,856 | +1.9% | 861,934 | 8.13 |
| 2025-02-14 | 6,876,231 | -1.8% | 653,276 | 10.53 |
| 2025-01-31 | 7,003,439 | -5.7% | 463,063 | 15.12 |
| 2025-01-15 | 7,424,946 | +1.1% | 713,110 | 10.41 |
| 2024-12-31 | 7,340,965 | +14.7% | 918,763 | 7.99 |
| 2024-12-13 | 6,400,100 | +5.2% | 1,400,689 | 4.57 |
| 2024-11-29 | 6,083,882 | +4.2% | 3,881,300 | 1.57 |
| 2024-11-15 | 5,841,190 | -0.3% | 741,408 | 7.88 |
| 2024-10-31 | 5,855,879 | +19.3% | 681,874 | 8.59 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of PYXS volume is 74.1%, up 17.3 points over the last five sessions. Over the last 30 readings it ranged from 33.3% (14 October 2026) to 74.1% (2 November 2026). The latest reading sits at the top of that range. The latest reading is 20.1 points above the 30-session average of 54.0%, on 437K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 324K | 437K | 74.1% | 0 |
| 2026-10-30 | 146K | 302K | 48.3% | 1,073 |
| 2026-10-29 | 130K | 335K | 38.8% | 95 |
| 2026-10-28 | 184K | 337K | 54.6% | 0 |
| 2026-10-27 | 237K | 596K | 39.8% | 0 |
| 2026-10-26 | 167K | 294K | 56.8% | 0 |
| 2026-10-23 | 173K | 356K | 48.6% | 0 |
| 2026-10-22 | 148K | 283K | 52.5% | 14 |
| 2026-10-21 | 135K | 262K | 51.6% | 0 |
| 2026-10-20 | 225K | 416K | 54.0% | 900 |
| 2026-10-19 | 243K | 460K | 52.9% | 1,500 |
| 2026-10-16 | 231K | 414K | 55.9% | 100 |
| 2026-10-15 | 139K | 291K | 48.0% | 0 |
| 2026-10-14 | 164K | 493K | 33.3% | 170 |
| 2026-10-13 | 175K | 417K | 42.1% | 3,500 |
| 2026-10-12 | 164K | 253K | 64.6% | 4,728 |
| 2026-10-09 | 184K | 414K | 44.3% | 0 |
| 2026-10-08 | 225K | 427K | 52.6% | 0 |
| 2026-10-07 | 276K | 415K | 66.6% | 43,006 |
| 2026-10-06 | 372K | 815K | 45.6% | 22,256 |
| 2026-10-05 | 357K | 569K | 62.8% | 1,020 |
| 2026-10-02 | 594K | 1.1M | 56.4% | 6,743 |
| 2026-10-01 | 1.1M | 1.8M | 62.7% | 97,031 |
| 2026-09-30 | 1.8M | 3.2M | 57.0% | 267,668 |
| 2026-09-29 | 52K | 75K | 68.6% | 0 |
| 2026-09-28 | 94K | 164K | 57.7% | 5,400 |
| 2026-09-25 | 173K | 297K | 58.2% | 32,401 |
| 2026-09-24 | 274K | 454K | 60.4% | 19,023 |
| 2026-09-23 | 137K | 226K | 60.5% | 2,900 |
| 2026-09-22 | 107K | 210K | 51.2% | 4,059 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in PYXS is 31 shares, down 7,438 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (19 August 2026) to 61,003 shares (8 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 31 | $2.90 | $90 |
| 2026-09-24 | 7,469 | $3.22 | $24K |
| 2026-09-23 | 85 | $3.36 | $286 |
| 2026-09-17 | 46,846 | $3.34 | $156K |
| 2026-09-11 | 15,104 | $3.27 | $49K |
| 2026-09-10 | 17,704 | $3.38 | $60K |
| 2026-09-09 | 17,768 | $3.89 | $69K |
| 2026-09-08 | 12,805 | $3.89 | $50K |
| 2026-09-02 | 1,480 | $3.44 | $5K |
| 2026-09-01 | 96 | $3.24 | $311 |
| 2026-08-31 | 3 | $3.23 | $10 |
| 2026-08-27 | 67 | $3.34 | $224 |
| 2026-08-20 | 1 | $3.37 | $3 |
| 2026-08-19 | 1 | $2.99 | $3 |
| 2026-08-12 | 179 | $2.83 | $507 |
| 2026-08-06 | 4 | $3.13 | $13 |
| 2026-08-05 | 2 | $3.16 | $6 |
| 2026-08-04 | 1,528 | $3.04 | $5K |
| 2026-08-03 | 88 | $2.65 | $233 |
| 2026-07-31 | 4,038 | $2.87 | $12K |
| 2026-07-30 | 9,589 | $2.92 | $28K |
| 2026-07-28 | 5 | $2.91 | $15 |
| 2026-07-27 | 7,246 | $2.61 | $19K |
| 2026-07-17 | 3,244 | $2.23 | $7K |
| 2026-07-13 | 14,206 | $2.67 | $38K |
| 2026-07-08 | 61,003 | $3.07 | $187K |
| 2026-07-06 | 70 | $2.63 | $184 |
| 2026-07-01 | 14,020 | $3.01 | $42K |
| 2026-06-30 | 4,274 | $2.86 | $12K |
| 2026-06-29 | 39,484 | $2.77 | $109K |
Insider trades
SEC Form 4, newest first. JSONInsiders at PYXS reported 1 open-market buy (price not stated in the filing) in the last 90 days and no open-market sells. Latest filing: GordonMD Global Investments LP (10% owner) on 2026-10-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-01 | GordonMD Global Investments LP | 10% owner | Buy | 5.5M | price not stated in the filing | not stated | 15.5M |
| 2026-06-30 | Dupont Jakob | Director | Sell | 35K | $3.06 | $107K | 39K |
| 2026-06-30 | Dupont Jakob | Director | Exercise or conversion | 35K | $1.60 | $56K | 74K |
| 2026-03-24 | Wadhane Jitendra | Prin Fin & Acct Officer | Grant | 109K | $0.00 | $0 | 513K |
| 2025-04-21 | HUMPHREY RACHEL | Director | Sell | 14K | $1.03 | $14K | 81K |
| 2025-04-17 | HUMPHREY RACHEL | Director | Sell | 200 | $0.97 | $194 | 95K |
| 2025-04-14 | HUMPHREY RACHEL | Director | Sell | 1K | $0.97 | $1K | 95K |
| 2024-11-26 | Connealy Pamela Ann | CFO & COO | Buy | 83K | $1.96 | $163K | 1.2M |
| 2024-11-26 | Connealy Pamela Ann | CFO & COO | Buy | 5K | $2.00 | $11K | 1.1M |
| 2024-06-07 | Palani Santhosh | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2024-03-26 | Wadhane Jitendra | SVP, Chief Accounting Officer | Grant | 131K | $0.00 | $0 | 398K |
| 2024-03-26 | HUMPHREY RACHEL | Director | Grant | 39K | $0.00 | $0 | 97K |
| 2024-03-26 | Dupont Jakob | Director | Grant | 39K | $0.00 | $0 | 39K |
| 2024-03-26 | Lewis-Hall Freda C | Director | Grant | 35K | $0.00 | $0 | 241K |
| 2024-03-26 | FLAVIN JOHN L | Director | Grant | 35K | $0.00 | $0 | 413K |
| 2024-03-26 | Cline Darren S | Director | Grant | 35K | $0.00 | $0 | 251K |
| 2024-03-26 | Connealy Pamela Ann | CFO & COO | Grant | 329K | $0.00 | $0 | 1.1M |
| 2023-11-29 | Connealy Pamela Ann | CFO and COO | Tax withholding | 37K | $1.40 | $52K | 782K |
| 2023-11-15 | Wadhane Jitendra | Chief Accounting Officer | Grant | 40K | $0.00 | $0 | 267K |
| 2023-09-28 | Connealy Pamela Ann | CFO and COO | Buy | 8K | $1.87 | $15K | 819K |
| 2023-09-27 | Connealy Pamela Ann | CFO and COO | Buy | 6K | $1.85 | $12K | 811K |
| 2023-09-27 | Wadhane Jitendra | Chief Accounting Officer | Buy | 3K | $1.87 | $5K | 227K |
| 2023-09-25 | Connealy Pamela Ann | CFO and COO | Buy | 12K | $1.67 | $20K | 804K |
| 2023-09-25 | Wadhane Jitendra | Chief Accounting Officer | Buy | 5K | $1.77 | $9K | 224K |
| 2023-09-22 | Connealy Pamela Ann | CFO and COO | Buy | 5K | $1.74 | $9K | 792K |
| 2023-09-22 | Wadhane Jitendra | Chief Accounting Officer | Buy | 3K | $1.74 | $4K | 219K |
| 2023-09-18 | Sullivan Lara | President and CEO | Sell | 9K | $2.10 | $18K | 2.4M |
| 2023-09-14 | Sullivan Lara | President and CEO | Sell | 100 | $2.25 | $225 | 2.4M |
| 2023-09-13 | Sullivan Lara | President and CEO | Tax withholding | 185K | $2.13 | $394K | 2.4M |
| 2023-09-13 | Sullivan Lara | President and CEO | Sell | 3K | $2.27 | $7K | 2.6M |
| 2023-09-12 | Sullivan Lara | President and CEO | Sell | 5K | $2.25 | $11K | 2.6M |
| 2023-09-11 | Sullivan Lara | President and CEO | Sell | 20K | $2.27 | $45K | 2.6M |
| 2023-09-07 | Sullivan Lara | President and CEO | Grant | 469K | $0.00 | $0 | 2.6M |
| 2023-09-07 | Wadhane Jitendra | Chief Accounting Officer | Grant | 94K | $0.00 | $0 | 212K |
| 2023-09-07 | Connealy Pamela Ann | CFO and COO | Grant | 188K | $0.00 | $0 | 782K |
| 2023-03-24 | Civik Thomas | Director | Grant | 139K | $0.00 | $0 | 206K |
| 2023-03-24 | Cline Darren S | Director | Grant | 139K | $0.00 | $0 | 216K |
| 2023-03-24 | FLAVIN JOHN L | Director | Grant | 139K | $0.00 | $0 | 378K |
| 2023-03-24 | HUMPHREY RACHEL | Director | Grant | 58K | $0.00 | $0 | 58K |
| 2023-03-24 | Lewis-Hall Freda C | Director | Grant | 139K | $0.00 | $0 | 206K |
| 2023-03-24 | Wadhane Jitendra | Chief Accounting Officer | Grant | 45K | $0.00 | $0 | 89K |
| 2023-03-24 | Wadhane Jitendra | Chief Accounting Officer | Grant | 29K | $0.00 | $0 | 118K |
| 2023-03-24 | Feingold Jay | Chief Medical Officer | Grant | 210K | $0.00 | $0 | 730K |
| 2023-03-24 | Yanchik Connealy Pamela | CFO and COO | Grant | 210K | $0.00 | $0 | 594K |
| 2023-03-24 | Sullivan Lara | President and CEO | Grant | 703K | $0.00 | $0 | 2.2M |
| 2023-03-17 | PFIZER INC | TenPercentOwner | Buy | 1.8M | $2.76 | $5.0M | 6.0M |
| 2023-01-03 | Yanchik Connealy Pamela | Chief Financial Officer | Grant | 43K | $0.00 | $0 | 385K |
| 2023-01-03 | Feingold Jay | Chief Medical Officer | Grant | 54K | $0.00 | $0 | 521K |
| 2023-01-03 | Sullivan Lara | Chief Executive Officer | Grant | 96K | $0.00 | $0 | 1.5M |
| 2022-04-21 | Chin Mark | Other | Sell | 1.7M | $3.05 | $5.3M | 0 |
| 2022-04-14 | Sullivan Lara | Chief Executive Officer | Grant | 315K | $0.00 | $0 | 1.4M |
| 2022-04-14 | Feingold Jay | Chief Medical Officer | Grant | 116K | $0.00 | $0 | 467K |
| 2022-04-14 | Yanchik Connealy Pamela | Chief Financial Officer | Grant | 93K | $0.00 | $0 | 341K |
| 2022-03-31 | Lewis-Hall Freda C | Director | Grant | 67K | $0.00 | $0 | 67K |
| 2022-03-31 | Cline Darren S | Director | Grant | 67K | $0.00 | $0 | 77K |
| 2022-03-31 | Yanchik Connealy Pamela | Chief Financial Officer | Grant | 248K | $0.00 | $0 | 248K |
| 2022-03-31 | Chin Mark | Director | Grant | 67K | $0.00 | $0 | 67K |
| 2022-03-31 | Feingold Jay | Chief Medical Officer | Grant | 307K | $0.00 | $0 | 351K |
| 2022-03-31 | Civik Thomas | Director | Grant | 67K | $0.00 | $0 | 67K |
| 2022-03-31 | FLAVIN JOHN L | Director | Grant | 67K | $0.00 | $0 | 238K |
| 2022-03-31 | Sullivan Lara | Chief Executive Officer | Grant | 743K | $0.00 | $0 | 1.0M |
| 2021-12-08 | Cline Darren S | Director | Buy | 10K | $9.39 | $94K | 10K |
| 2021-11-18 | Civik Thomas | Director | Buy | 16K | $12.74 | $200K | 16K |
| 2021-10-13 | Cormorant Asset Management, LP | Other | Conversion | 669K | price not stated in the filing | not stated | 669K |
| 2021-10-13 | Cormorant Asset Management, LP | Other | Buy | 450K | $16.00 | $7.2M | 1.1M |
| 2021-10-13 | Bayer World Investments B.V. | Other | Conversion | 2.7M | price not stated in the filing | not stated | 2.7M |
| 2021-10-13 | FLAVIN JOHN L | Director | Conversion | 2K | price not stated in the filing | not stated | 172K |
| 2021-10-13 | Chin Mark | Director | Conversion | 1.4M | price not stated in the filing | not stated | 1.4M |
| 2021-10-13 | Chin Mark | Director | Buy | 313K | $16.00 | $5.0M | 1.7M |
| 2021-10-07 | Feingold Jay | Chief Medical Officer | Grant | 44K | $0.00 | $0 | 44K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for PYXS worth $107K at the prices reported; 0 in the last 90 days worth $0. Latest: Dupont Jakob filed on 2026-06-30 to sell 35,000 shares ($107K) from 2026-06-30.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-06-30 | Dupont JakobDirector | 35K | $107K | 0.055% | 2026-06-30 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON18 holders report 5% or more of PYXS in their latest filing, all on Schedule 13G (passive). The largest reported stake is GordonMD Global Investments LP at 16.4% of the class (20,441,948 shares), filed 2026-10-09 for an event on 2026-10-01.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-09 | 13G/Ano. 3 | GordonMD Global Investments LPinvestment adviser, partnership | 20.4M | 16.4% | 2026-10-01 |
| 2026-10-09 | 13G/Ano. 3 | GordonMD Long Biased Master Fund LPpartnership | 20.4M | 16.4% | 2026-10-01 |
| 2026-10-09 | 13G/Ano. 3 | GordonMD Long Biased GP LLCother entity | 20.4M | 16.4% | 2026-10-01 |
| 2026-10-09 | 13G/Ano. 3 | Craig D. Gordonparent holding company, individual | 20.4M | 16.4% | 2026-10-01 |
| 2026-10-05 | 13G | Coastlands Capital LPinvestment adviser, partnership | 6.4M | 5.4% | 2026-10-01 |
| 2026-10-05 | 13G | Coastlands Capital Partners LPpartnership | 6.4M | 5.4% | 2026-10-01 |
| 2026-10-05 | 13G | Coastlands Capital GP LLCother entity | 6.4M | 5.4% | 2026-10-01 |
| 2026-10-05 | 13G | Coastlands Capital LLCparent holding company, other entity | 6.4M | 5.4% | 2026-10-01 |
| 2026-10-05 | 13G | Matthew D. Perryparent holding company, individual | 6.4M | 5.4% | 2026-10-01 |
| 2026-07-10 | 13G | BVF INC/ILcorporation | 8.3M | 10.0% | 2026-07-02 |
| 2026-07-10 | 13G | BVF PARTNERS L P/ILinvestment adviser, partnership | 8.3M | 10.0% | 2026-07-02 |
| 2026-07-10 | 13G | LAMPERT MARK Nindividual | 8.3M | 10.0% | 2026-07-02 |
| 2026-07-10 | 13G | BVF GP HOLDINGS LLCother entity | 7.7M | 9.2% | 2026-07-02 |
| 2026-07-10 | 13G | BIOTECHNOLOGY VALUE FUND L Ppartnership | 4.6M | 5.5% | 2026-07-02 |
| 2026-07-10 | 13G | BVF I GP LLCother entity | 4.6M | 5.5% | 2026-07-02 |
| 2026-07-10 | 13G | BVF II GP LLCother entity | 3.1M | 3.7% | 2026-07-02 |
| 2026-07-10 | 13G | BIOTECHNOLOGY VALUE FUND II LPpartnership | 3.1M | 3.7% | 2026-07-02 |
| 2026-07-10 | 13G | BVF Partners OS Ltd.corporation | 518K | 0.6% | 2026-07-02 |
| 2026-07-10 | 13G | Biotechnology Value Trading Fund OS LPpartnership | 518K | 0.6% | 2026-07-02 |
| 2026-02-09 | 13G/Ano. 2 | Laurion Capital Management LPinvestment adviser, partnership | 4.8M | 7.7% | 2025-12-31 |
| 2026-02-09 | 13G/Ano. 2 | Benjamin Alexander Smithparent holding company, individual | 4.8M | 7.7% | 2025-12-31 |
| 2026-02-09 | 13G/Ano. 2 | Janaka Sheehan Maduraperumaparent holding company, individual | 4.8M | 7.7% | 2025-12-31 |
| 2025-10-14 | 13G/Ano. 1 | Millennium Management LLCother entity | 818K | 1.3% | 2025-09-30 |
| 2025-10-14 | 13G/Ano. 1 | Millennium Group Management LLCother entity | 818K | 1.3% | 2025-09-30 |
| 2025-10-14 | 13G/Ano. 1 | Israel A. Englanderindividual | 818K | 1.3% | 2025-09-30 |
13F holders
Tracked managers holding PYXS at their latest 13F. JSON5 of the 30 tracked managers held PYXS at their latest 13F, $3.5M in total at quarter-end prices. Renaissance Technologies is the largest at $2.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 3 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 772K | $2.3M | 0.00% | -116K |
| Millennium Management | 2026-06-30 | 233K | $701K | 0.00% | -165K |
| Two Sigma Investments | 2026-06-30 | 84K | $253K | 0.00% | +11K |
| Citadel Advisors | 2026-06-30 | 47K | $142K | 0.00% | -14K |
| Point72 Asset Management | 2026-06-30 | 37K | $112K | 0.00% | +5K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Pyxis Oncology in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Pyxis Oncology (PYXS), SEC CIK 1782223, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-06-30.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-09.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-13.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1782223Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of PYXS is sold short?
4,345,953 shares were held short at the 2026-10-15 settlement, 3.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is PYXS's daily short volume?
On 2026-11-02, 324,141 of the 437,368 PYXS shares reported to FINRA were sold short, 74.1% of the day's reported volume. Short volume is a flow for one day, not a position.
Does PYXS have fails to deliver?
The SEC's latest file shows 31 PYXS shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are PYXS insiders buying or selling?
Insiders at PYXS reported 1 open-market buy (price not stated in the filing) in the last 90 days and no open-market sells. Latest filing: GordonMD Global Investments LP (10% owner) on 2026-10-01.
Have PYXS insiders filed to sell?
1 Form 144 notice on file for PYXS worth $107K at the prices reported; 0 in the last 90 days worth $0. Latest: Dupont Jakob filed on 2026-06-30 to sell 35,000 shares ($107K) from 2026-06-30.
Who owns 5% or more of PYXS?
18 holders report 5% or more of PYXS in their latest filing, all on Schedule 13G (passive). The largest reported stake is GordonMD Global Investments LP at 16.4% of the class (20,441,948 shares), filed 2026-10-09 for an event on 2026-10-01.
Which tracked 13F managers own PYXS?
5 of the 30 tracked 13F managers held PYXS shares at their latest filing, $3.5M in all. The largest: Renaissance Technologies (772K shares, $2.3M), Izzy Englander's Millennium Management (233K shares, $701K), Two Sigma Investments (84K shares, $253K), Ken Griffin's Citadel Advisors (47K shares, $142K), Steve Cohen's Point72 Asset Management (37K shares, $112K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.